Mc Guire Investment Group, LLC Intellia Therapeutics, Inc. Transaction History

Mc Guire Investment Group, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 10, 2024	SELL	$19.72 - $27.36 $13,665 - $18,960	-693 Reduced 0.96%	71,301 $1.47 Million
Q2 2024 Jul 23, 2024	SELL	$20.02 - $27.22 $90,049 - $122,435	-4,498 Reduced 5.88%	71,994 $1.61 Million
Q1 2024 Apr 26, 2024	BUY	$23.82 - $32.8 $618,915 - $852,242	25,983 Added 51.44%	76,492 $2.1 Million
Q4 2023 Jan 12, 2024	SELL	$23.16 - $32.34 $358,401 - $500,461	-15,475 Reduced 23.45%	50,509 $1.54 Million
Q3 2023 Oct 12, 2023	BUY	$31.62 - $45.78 $80,631 - $116,739	2,550 Added 4.02%	65,984 $2.09 Million
Q2 2023 Jul 18, 2023	BUY	$34.58 - $46.03 $381,106 - $507,296	11,021 Added 21.03%	63,434 $2.59 Million
Q1 2023 Apr 20, 2023	BUY	$33.3 - $44.82 $577,155 - $776,820	17,332 Added 49.41%	52,413 $1.95 Million
Q4 2022 Jan 10, 2023	BUY	$33.21 - $62.69 $1.17 Million - $2.2 Million	35,081 New	35,081 $0

315

90.6M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $784M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Mc Guire Investment Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Mc Guire Investment Group, LLC with notifications on news.